On September 15, 2025, at 4:08 PM Eastern Time, Monopar Therapeutics announced encouraging findings from recent clinical evaluations. The firm shared results from three investigations examining a treatment targeting neurological complications in patients with Wilson disease—a genetic condition that disrupts the body's copper regulation. The disorder can lead to problems with the liver, kidneys, and eyes while also causing joint pain and an increased risk of bone fractures.
In these investigations, the experimental medication ALXN1840 demonstrated lasting improvements for patients over an extended period. The treatment preserved neurological benefits for over six years, with a median follow-up period of roughly 2.6 years. Both patients and their physicians noticed clear improvements in neurological symptoms. In cases where individuals initially received conventional medications and later transitioned to ALXN1840, noticeable improvements were recorded, whereas switching from ALXN1840 to standard regimens resulted in a reduction in neurological function. The drug works by binding to copper, thereby lowering its concentration in the bloodstream.
Market activity mirrored the positive clinical news as Monopar’s shares climbed nearly 11% to close at $54.49 after breaking above a technical pattern characterized by a cup base formation with an entry point around $50.14. An analyst at Oppenheimer commented that long-term data continue to support ALXN1840’s capability in addressing neurological disturbances, psychiatric challenges, and liver complications encountered by more than half of Wilson disease patients. The analyst has set a target price of $77 for the stock, and all nine experts tracking the security rate it as a buy. This performance places Monopar Therapeutics among the top performers in the biotech sector, with its stock ranking in the highest 1% based on recent market strength measures.
Safety outcomes from the studies proved reassuring. Fewer than 5% of participants experienced serious side effects associated with the medication, and reports of neurological adverse events were noted in less than 1% of patients. These results lay the groundwork for the company to prepare a submission to the Food and Drug Administration in the upcoming quarter. This encouraging data offers hope to patients with Wilson disease and may draw additional interest from investors and industry observers. This advancement may signal continued progress in treatment options.
